Search Results - "Mafficini, A"

The active space debris removal mission RemoveDebris. Part 2: In orbit operations by Aglietti, Guglielmo S., Taylor, Ben, Fellowes, Simon, Salmon, Thierry, Retat, Ingo, Hall, Alexander, Chabot, Thomas, Pisseloup, Aurélien, Cox, C., Zarkesh, A., Mafficini, A., Vinkoff, N., Bashford, K., Bernal, Cesar, Chaumette, François, Pollini, Alexandre, Steyn, Willem H.

“…This is the second of two companion papers that describe the development of the RemoveDEBRIS space mission. This second article describes the in-orbit…”
Get full text

Integrative characterization of pancreatic ductal adenocarcinoma with poorly cohesive / signet ring cells by Luchini, Claudio, Simbolo, M., Silvestris, N., Mafficini, A., Maggino, L., Malleo, G., Mattiolo, P., Salvia, R., Lawlor, R., Scarpa, A.

Get full text

Hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms by Mattiolo, Paola, Mafficini, A., Lawlor, R., Marchegiani, G., Malleo, G., Pea, A., Salvia, R., Adsay, V., Scarpa, A., Luchini, C.

Get full text

Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis by Bria, E., Pilotto, S., Simbolo, M., Fassan, M., de Manzoni, G., Carbognin, L., Sperduti, I., Brunelli, M., Cataldo, I., Tomezzoli, A., Mafficini, A., Turri, G., Karachaliou, N., Rosell, R., Tortora, G., Scarpa, A.

“…In this study, we evaluated whether the presence of genetic alterations detected by next generation sequencing may define outcome in a prognostically-selected…”
Get full text

Solid pseudopapillary neoplasm of the pancreas and abdominal desmoid tumor in a patient carrying two different BRCA2 germline mutations by Mafficini, A., Ghimenton, C., Antonello, D., Cantù, C., Salvia, R., Marchegiani, G., Malleo, G., Piredda, M., Paolino, G., Mattiolo, P., Lawlor, R., Luchini, C.

Get full text

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer by Lote, H., Spiteri, I., Ermini, L., Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J.C., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M., Werner, B., Lise, S., Aktipis, A., Maley, C., Greaves, M., Braconi, C., White, J., Fassan, M., Scarpa, A., Sottoriva, A., Valeri, N.

“…Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers…”
Get full text

Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models by Gkountakos, A., Pilotto, S., Simbolo, M., Vicentini, C., Mafficini, A., del Curatolo, A., Scarpa, A., Tortora, G., Corbo, V., Bria, E.

Get full text

Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers by Simbolo, M., Mafficini, A., Vicentini, C., Ruzzenente, A., Rusev, B., Brunelli, M., Pedron, S., Bertuzzo, F., Barbi, S., Fassan, M., Corbo, V., Bagante, F., Turri, G., Luchini, C., Lawlor, R., Guglielmi, A., Bassi, C., Scarpa, A.

Get full text

Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations by Pilotto, S., Grizzi, G., Sperduti, I., Simbolo, M., Vicentini, C., Caliò, A., Caccese, M., Mafficini, A., Carbognin, L., Corbo, V., Gkountakos, A., Santo, A., Infante, M., Brunelli, M., Scarpa, A., Tortora, G., Bria, E.

Get full text

Splicing machinery dysregulation and its relationship with PDAC aggressiveness by Perez, E. Alors, Blázquez-Encinas, R., Mafficini, A., Montilla, T. Moreno, Viyuela-Garcia, C., Jiménez-Vacas, J.M., Sánchez-Hidalgo, J.M., Berbel, I., Marín-Sanz, J.A., Sánchez-Fría, M.E., Luchini, C., Pea, A., Ventura, S., Gahete, M.D., Arjona-Sánchez, Á., Lawlor, R.T., Luque, R.M., Scarpa, A., Ibáñez-Costa, A., Castaño, J.P.

Get full text

A functional role for splicing factor EIF4A3 dysregulation in pancreatic ductal adenocarcinoma by Blazquez-Encinas, R., Alors-Pérez, E., Mafficini, A., Moreno-Montilla, T., Viyuela-García, C., Abollo-Jiménez, F., Sánchez-Hidalgo, J.M., Sánchez-Frías, M.E., García-Vioque, V., Luchini, C., Pea, A., Ventura, S., Gahete, M.D., Arjona, Á., Lawlor, R.T., Luque, R.M., Scarpa, A., Ibáñez-Costa, A., Castaño, J.P.

Get full text

Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target by Pilotto, S., Simbolo, M., Gkountakos, A., Mafficini, A., Vicentini, C., Sperduti, I., Ludovini, V., Chiari, R., Novello, S., Milella, M., Carbognin, L., Caregnato, E., Santo, A., Infante, M., Brunelli, M., Corbo, V., Scarpa, A., Tortora, G., Bria, E.

Get full text

Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities by Simbolo, M., Centonze, G., Ali, G., Garzone, G., Taormina, S., Sabella, G., Ciaparrone, C., Mafficini, A., Grillo, F., Mangogna, A., Volante, M., Mastracci, L., Fontanini, G., Pilotto, S., Bria, E., Infante, M., Capella, C., Rolli, L., Pastorino, U., Milella, M., Milione, M., Scarpa, A.

“…Combined small-cell lung cancer (C-SCLC) is composed of SCLC admixed with a non-small-cell cancer component. They currently receive the same treatment as SCLC…”
Get full text

Expression of transmembrane protein tyrosine phosphatase gamma (PTPγ) in normal and neoplastic human tissues by Vezzalini, M, Mombello, A, Menestrina, F, Mafficini, A, Della Peruta, M, Van Niekerk, C, Barbareschi, M, Scarpa, A, Sorio, C

“…Aims:  To establish the conditions for protein tyrosine phosphatase gamma (PTPγ) detection in paraffin tissues using two antibodies raised against its NH2‐…”
Get full text

17 Modulation of cystic fibrosis disease severity by macrophage migration inhibitory factor polymorphisms by Leal, T, Mafficini, A, Lebecque, P, Ortombina, M, Pintani, E, Pepermans, X, Sorio, C, Assael, B.M, Melotti, P

Get full text

Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts by Saraga, G, Mafficini, A, Ghaneh, P, Sorio, C, Costello, E

“…Few effective treatments for pancreatic cancer exist, especially for patients with advanced disease. Gene therapy alone, or combined with current treatments,…”
Get full text

Impact of the polymorphic variant 5 FR/G-260C in the Multidrug Resistance-associate Protein-1 gene on severity of cystic fibrosis by Mafficini, A, Ortombina, M, Sermet-Gaudelus, I, Lebecque, P, Leal, T, Leonard, A, Reychler, G, Dahan, K, Papermans, X, Lenoir, G, Sorio, C, Iansa, P, Assael, B.M, Melotti, P

Get full text

1683P Implementing next generation sequencing (NGS)/molecular tumor board (MTB)-based precision oncology practice: One-year experience at the Verona University Hospital by Riva, S.T., Luchini, C., Zacchi, F., Mafficini, A., Borghesani, M., Mongillo, M., Scaglione, I.M., Manduca, S., Lucin, E., Moscarda, V., Pafumi, S., Leta, L.C., Dodi, A., Reni, A., Messineo, L., Chiamulera, C., Urso, E.D.L., Scarpa, A., Lawlor, R., Milella, M.

Get full text

Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases by Mafficini, A., Cantù, C., Antonello, D., Simbolo, M., Piredda, L., Lever, V., Rusev, B., Pecori, S., Milella, M., Lawlor, R.T., Scarpa, A.

Get full text

1405PValidation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases by Mafficini, A, Cantù, C, Antonello, D, Simbolo, M, Piredda, L, Lever, V, Rusev, B, Pecori, S, Milella, M, Lawlor, R T, Scarpa, A

“…Abstract Background Colorectal carcinoma 5-year survival ranges from 90% in patients with localized disease to 15% for those with distant metastasis. Recent…”
Get full text